View Past PerformanceGenetec バランスシートの健全性財務の健全性 基準チェック /46Genetecの総株主資本は¥2.7B 、総負債は¥2.1Bで、負債比率は75.6%となります。総資産と総負債はそれぞれ¥6.9Bと¥4.2Bです。 Genetecの EBIT は¥821.0Mで、利息カバレッジ比率29.3です。現金および短期投資は¥1.6Bです。主要情報75.61%負債資本比率JP¥2.06b負債インタレスト・カバレッジ・レシオ29.3x現金JP¥1.60bエクイティJP¥2.73b負債合計JP¥4.19b総資産JP¥6.91b財務の健全性に関する最新情報分析記事 • May 16Genetec (TSE:4492) Could Easily Take On More DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 11Is Genetec (TSE:4492) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Aug 02Does Genetec (TSE:4492) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...すべての更新を表示Recent updates分析記事 • May 21With EPS Growth And More, Genetec (TSE:4492) Makes An Interesting CaseFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥44.22 (vs JP¥36.80 in FY 2025)Full year 2026 results: EPS: JP¥44.22 (up from JP¥36.80 in FY 2025). Revenue: JP¥11.0b (up 35% from FY 2025). Net income: JP¥510.0m (up 21% from FY 2025). Profit margin: 4.6% (down from 5.2% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • May 18Genetec Corporation, Annual General Meeting, Jun 26, 2026Genetec Corporation, Annual General Meeting, Jun 26, 2026.Valuation Update With 7 Day Price Move • May 18Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥387, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 14x in the IT industry in Japan. Total returns to shareholders of 45% over the past three years.Upcoming Dividend • Mar 23Upcoming dividend of JP¥11.50 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 11 June 2026. Payout ratio is a comfortable 53% but the company is not cash flow positive. Trailing yield: 4.2%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.8%).Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥8.40 (vs JP¥2.18 in 3Q 2025)Third quarter 2026 results: EPS: JP¥8.40 (up from JP¥2.18 in 3Q 2025). Revenue: JP¥2.74b (up 49% from 3Q 2025). Net income: JP¥97.0m (up 288% from 3Q 2025). Profit margin: 3.5% (up from 1.4% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year whereas the company’s share price has increased by 45% per year.お知らせ • Dec 02Genetec Corporation to Report Q3, 2026 Results on Feb 13, 2026Genetec Corporation announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Dec 02New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.5% Last year net profit margin: 6.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (3.5% net profit margin). Market cap is less than US$100m (JP¥5.11b market cap, or US$32.9m).Upcoming Dividend • Sep 22Upcoming dividend of JP¥8.00 per shareEligible shareholders must have bought the stock before 29 September 2025. Payment date: 02 December 2025. Payout ratio is a comfortable 53% and the cash payout ratio is 96%. Trailing yield: 3.9%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.2%).お知らせ • Sep 02Genetec Corporation to Report Q2, 2026 Results on Nov 14, 2025Genetec Corporation announced that they will report Q2, 2026 results on Nov 14, 2025Reported Earnings • Aug 11First quarter 2026 earnings released: EPS: JP¥1.48 (vs JP¥4.56 in 1Q 2025)First quarter 2026 results: EPS: JP¥1.48 (down from JP¥4.56 in 1Q 2025). Revenue: JP¥2.49b (up 23% from 1Q 2025). Net income: JP¥17.0m (down 67% from 1Q 2025). Profit margin: 0.7% (down from 2.6% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.分析記事 • Jul 31Genetec Corporation (TSE:4492) Might Not Be As Mispriced As It LooksWith a median price-to-earnings (or "P/E") ratio of close to 14x in Japan, you could be forgiven for feeling...お知らせ • Jun 27Genetec Corporation to Report Q1, 2026 Results on Aug 08, 2025Genetec Corporation announced that they will report Q1, 2026 results on Aug 08, 2025Reported Earnings • May 21Full year 2025 earnings released: EPS: JP¥36.80 (vs JP¥36.38 in FY 2024)Full year 2025 results: EPS: JP¥36.80 (up from JP¥36.38 in FY 2024). Revenue: JP¥8.12b (up 14% from FY 2024). Net income: JP¥421.0m (up 1.7% from FY 2024). Profit margin: 5.2% (down from 5.8% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 20Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥432, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 18x in the IT industry in Japan. Total returns to shareholders of 79% over the past three years.分析記事 • May 16Genetec (TSE:4492) Could Easily Take On More DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • May 16Genetec Corporation, Annual General Meeting, Jun 27, 2025Genetec Corporation, Annual General Meeting, Jun 27, 2025.分析記事 • Apr 19Take Care Before Diving Into The Deep End On Genetec Corporation (TSE:4492)There wouldn't be many who think Genetec Corporation's ( TSE:4492 ) price-to-earnings (or "P/E") ratio of 14.3x is...New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (JP¥4.71b market cap, or US$32.2m).Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to JP¥411, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 15x in the IT industry in Japan. Total returns to shareholders of 60% over the past three years.Upcoming Dividend • Mar 21Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 10 June 2025. Payout ratio is a comfortable 60% and this is well supported by cash flows. Trailing yield: 4.3%. Within top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.4%).お知らせ • Mar 11Genetec Corporation to Report Fiscal Year 2025 Results on May 15, 2025Genetec Corporation announced that they will report fiscal year 2025 results on May 15, 2025お知らせ • Feb 25Genetec Corporation (TSE:4492) agreed to acquire Morson Japan Co.,Ltd. from Yasunori Morikawa and others for ¥800 million.Genetec Corporation (TSE:4492) agreed to acquire Morson Japan Co.,Ltd. from Yasunori Morikawa and others for ¥800 million on February 25, 2025. For the period ending March 31, 2024, Morson Japan Co.,Ltd. reported total revenue of ¥2.52 billion, EBIT of ¥34 million and net income of ¥20 million. As of March 31, 2024, Morson Japan Co.,Ltd. reported total assets of ¥2.01 billion and total common equity of ¥898 million. The expected completion of the transaction is March 6, 2025.Reported Earnings • Feb 15Third quarter 2025 earnings released: EPS: JP¥2.18 (vs JP¥6.94 in 3Q 2024)Third quarter 2025 results: EPS: JP¥2.18 (down from JP¥6.94 in 3Q 2024). Revenue: JP¥1.84b (up 3.4% from 3Q 2024). Net income: JP¥25.0m (down 68% from 3Q 2024). Profit margin: 1.4% (down from 4.5% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (JP¥5.97b market cap, or US$39.1m).Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥520, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 18x in the IT industry in Japan. Total returns to shareholders of 93% over the past three years.お知らせ • Jan 03Genetec Corporation to Report Q3, 2025 Results on Feb 14, 2025Genetec Corporation announced that they will report Q3, 2025 results on Feb 14, 2025分析記事 • Nov 11Is Genetec (TSE:4492) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Buy Or Sell Opportunity • Nov 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.1% to JP¥598. The fair value is estimated to be JP¥753, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 41%.お知らせ • Oct 01Genetec Corporation to Report Q2, 2025 Results on Nov 14, 2024Genetec Corporation announced that they will report Q2, 2025 results on Nov 14, 2024Upcoming Dividend • Sep 20Upcoming dividend of JP¥8.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 02 December 2024. Payout ratio is a comfortable 42% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (1.4%).Buy Or Sell Opportunity • Sep 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.2% to JP¥606. The fair value is estimated to be JP¥763, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 41%.Reported Earnings • Aug 11First quarter 2025 earnings released: EPS: JP¥4.56 (vs JP¥1.67 loss in 1Q 2024)First quarter 2025 results: EPS: JP¥4.56 (up from JP¥1.67 loss in 1Q 2024). Revenue: JP¥2.01b (up 40% from 1Q 2024). Net income: JP¥52.0m (up JP¥71.0m from 1Q 2024). Profit margin: 2.6% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.分析記事 • Aug 05Positive Sentiment Still Eludes Genetec Corporation (TSE:4492) Following 34% Share Price SlumpUnfortunately for some shareholders, the Genetec Corporation ( TSE:4492 ) share price has dived 34% in the last thirty...New Risk • Aug 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (JP¥5.42b market cap, or US$38.0m).分析記事 • Aug 02Does Genetec (TSE:4492) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Valuation Update With 7 Day Price Move • Aug 02Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥574, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 18x in the IT industry in Japan. Total returns to shareholders of 115% over the past three years.お知らせ • Jun 05Genetec Corporation to Report Q1, 2025 Results on Aug 09, 2024Genetec Corporation announced that they will report Q1, 2025 results on Aug 09, 2024分析記事 • May 23Genetec Corporation's (TSE:4492) Popularity With Investors Under Threat As Stock Sinks 27%Genetec Corporation ( TSE:4492 ) shares have had a horrible month, losing 27% after a relatively good period...Reported Earnings • May 21Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: JP¥36.38 (up from JP¥2.03 in FY 2023). Revenue: JP¥7.15b (up 22% from FY 2023). Net income: JP¥414.0m (up JP¥391.0m from FY 2023). Profit margin: 5.8% (up from 0.4% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 139%. Revenue is forecast to stay flat during the next 2 years compared to a 5.0% growth forecast for the IT industry in Japan. Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 36% per year.お知らせ • May 17Genetec Corporation, Annual General Meeting, Jun 25, 2024Genetec Corporation, Annual General Meeting, Jun 25, 2024.Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to JP¥732, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 19x in the IT industry in Japan. Total returns to shareholders of 165% over the past three years.お知らせ • Apr 02Genetec Corporation to Report Fiscal Year 2024 Results on May 15, 2024Genetec Corporation announced that they will report fiscal year 2024 results on May 15, 2024Upcoming Dividend • Mar 21Upcoming dividend of JP¥6.50 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 17 June 2024. Payout ratio is a comfortable 4.7% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Japanese dividend payers (3.2%). Lower than average of industry peers (1.4%).分析記事 • Feb 26Genetec Corporation (TSE:4492) Stock Rockets 38% As Investors Are Less Pessimistic Than ExpectedGenetec Corporation ( TSE:4492 ) shares have continued their recent momentum with a 38% gain in the last month alone...Reported Earnings • Feb 19Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: JP¥1.77b (up 30% from 3Q 2023). Net income: JP¥79.0m (up JP¥129.0m from 3Q 2023). Profit margin: 4.5% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the IT industry in Japan. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to JP¥742, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 18x in the IT industry in Japan. Total returns to shareholders of 151% over the past three years.New Risk • Jan 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.4% average weekly change). Minor Risk Market cap is less than US$100m (JP¥7.26b market cap, or US$49.1m).Valuation Update With 7 Day Price Move • Jan 18Investor sentiment improves as stock rises 20%After last week's 20% share price gain to JP¥637, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 19x in the IT industry in Japan. Total returns to shareholders of 92% over the past three years.New Risk • Dec 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (JP¥5.65b market cap, or US$38.1m).お知らせ • Nov 29Genetec Corporation to Report Q3, 2024 Results on Feb 14, 2024Genetec Corporation announced that they will report Q3, 2024 results on Feb 14, 2024Reported Earnings • Nov 17Second quarter 2024 earnings releasedSecond quarter 2024 results: EPS: JP¥36.38. Revenue: JP¥1.72b (up 29% from 2Q 2023). Net income: JP¥138.0m (up JP¥138.0m from 2Q 2023). Profit margin: 8.0% (up from 0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the IT industry in Japan. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Nov 14Investor sentiment improves as stock rises 25%After last week's 25% share price gain to JP¥1,320, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the IT industry in Japan. Total returns to shareholders of 42% over the past three years.お知らせ • Sep 28Genetec Corporation to Report Q2, 2024 Results on Nov 14, 2023Genetec Corporation announced that they will report Q2, 2024 results on Nov 14, 2023Reported Earnings • Aug 12First quarter 2024 earnings released: JP¥5.02 loss per share (vs JP¥34.94 loss in 1Q 2023)First quarter 2024 results: JP¥5.02 loss per share (improved from JP¥34.94 loss in 1Q 2023). Revenue: JP¥1.44b (up 20% from 1Q 2023). Net loss: JP¥19.0m (loss narrowed 86% from 1Q 2023). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the IT industry in Japan.お知らせ • Jun 29Genetec Corporation to Report Q1, 2024 Results on Aug 10, 2023Genetec Corporation announced that they will report Q1, 2024 results on Aug 10, 2023Reported Earnings • May 19Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: JP¥6.10 (down from JP¥15.02 in FY 2022). Revenue: JP¥5.86b (up 25% from FY 2022). Net income: JP¥23.0m (down 59% from FY 2022). Profit margin: 0.4% (down from 1.2% in FY 2022). Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates by 60%. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the IT industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Mar 23Upcoming dividend of JP¥10.00 per share at 2.0% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 14 June 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.0%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.7%).Reported Earnings • Feb 17Third quarter 2023 earnings released: JP¥13.22 loss per share (vs JP¥1.87 loss in 3Q 2022)Third quarter 2023 results: JP¥13.22 loss per share (further deteriorated from JP¥1.87 loss in 3Q 2022). Revenue: JP¥1.36b (up 25% from 3Q 2022). Net loss: JP¥50.0m (loss widened JP¥43.0m from 3Q 2022). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the IT industry in Japan.お知らせ • Dec 14Genetec Corporation (TSE:4492) agreed to acquire Topwell Co., Ltd. from Yasuhide Inoue for ¥547 million.Genetec Corporation (TSE:4492) agreed to acquire Topwell Co., Ltd. from Yasuhide Inoue for ¥547 million on December 13, 2022. For the period ended March 31, 2022, Topwell reported Net assets of ¥34 million, Total assets of ¥120 million, sales of ¥186 million, Operating income of ¥9 million, and Net income of ¥3 million. Transaction is expected to close on December 14, 2022.お知らせ • Dec 02Genetec Corporation to Report Q3, 2023 Results on Feb 14, 2023Genetec Corporation announced that they will report Q3, 2023 results on Feb 14, 2023Reported Earnings • Nov 16Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: JP¥1.33b (up 25% from 2Q 2022). Net income: JP¥0 (down JP¥15.0m from profit in 2Q 2022). Profit margin: 0% (down from 1.4% in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the IT industry in Japan.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Outside Director Midori Mizutani was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 28Genetec Corporation to Report Q2, 2023 Results on Nov 14, 2022Genetec Corporation announced that they will report Q2, 2023 results on Nov 14, 2022Reported Earnings • Aug 12First quarter 2023 earnings released: JP¥34.94 loss per share (vs JP¥19.20 profit in 1Q 2022)First quarter 2023 results: JP¥34.94 loss per share (down from JP¥19.20 profit in 1Q 2022). Revenue: JP¥1.20b (up 10.0% from 1Q 2022). Net loss: JP¥131.0m (down 285% from profit in 1Q 2022). Over the next year, revenue is forecast to grow 12%, compared to a 11% growth forecast for the industry in Japan.お知らせ • Jul 07Genetec Corporation to Report Q1, 2023 Results on Aug 10, 2022Genetec Corporation announced that they will report Q1, 2023 results on Aug 10, 2022Reported Earnings • May 18Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: JP¥15.02 (down from JP¥47.20 in FY 2021). Revenue: JP¥4.68b (up 15% from FY 2021). Net income: JP¥56.0m (down 68% from FY 2021). Profit margin: 1.2% (down from 4.2% in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 253%. Over the next year, revenue is forecast to grow 12%, compared to a 8.0% growth forecast for the industry in Japan.お知らせ • May 18Genetec Corporation, Annual General Meeting, Jun 28, 2022Genetec Corporation, Annual General Meeting, Jun 28, 2022.Board Change • Apr 27No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. GM of Management Headquarters & Director Akihiro Suzuki was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.お知らせ • Apr 08Genetec Corporation to Report Fiscal Year 2022 Results on May 16, 2022Genetec Corporation announced that they will report fiscal year 2022 results on May 16, 2022Upcoming Dividend • Mar 23Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 08 June 2022. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (1.5%).Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥1.87 loss per share (down from JP¥8.13 profit in 3Q 2021). Revenue: JP¥1.09b (up 13% from 3Q 2021). Net loss: JP¥7.00m (down 123% from profit in 3Q 2021). Revenue was in line with analyst estimates.お知らせ • Jan 26Genetec Corporation (JASDAQ:4492) agreed to acquire BART Co., Ltd. from Hitoshi Fujita and others.Genetec Corporation (JASDAQ:4492) agreed to acquire BART Co., Ltd. from Hitoshi Fujita and others on January 24, 2022. The deal is subject to approval from Genetec Corporation (JASDAQ:4492) board. As of January 24, 2022 Genetec Corporation (JASDAQ:4492) board approved the deal. For the year ended September 30, 2021 BART Co., Ltd. recorded the total assets of ¥95 million, net assets of ¥42 million, sales of ¥128 million, operating profit of ¥9 million, net income ¥5 million. The deal is expected to close on January 25, 2022.Valuation Update With 7 Day Price Move • Jan 24Investor sentiment improved over the past weekAfter last week's 19% share price gain to JP¥859, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 19x in the IT industry in Japan. Total loss to shareholders of 16% over the past year.Reported Earnings • Nov 19Second quarter 2022 earnings released: EPS JP¥4.02 (vs JP¥8.13 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: JP¥1.07b (up 10.0% from 2Q 2021). Net income: JP¥15.0m (down 50% from 2Q 2021). Profit margin: 1.4% (down from 3.1% in 2Q 2021). The decrease in margin was driven by higher expenses.Upcoming Dividend • Sep 22Upcoming dividend of JP¥4.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 01 December 2021. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.0%). Lower than average of industry peers (1.2%).Valuation Update With 7 Day Price Move • Sep 06Investor sentiment deteriorated over the past weekAfter last week's 47% share price decline to JP¥951, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 23x in the IT industry in Japan. Total loss to shareholders of 49% over the past year.Reported Earnings • May 18Full year 2021 earnings released: EPS JP¥94.39 (vs JP¥141 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥4.08b (down 14% from FY 2020). Net income: JP¥173.0m (down 18% from FY 2020). Profit margin: 4.2% (down from 4.5% in FY 2020). The decrease in margin was driven by lower revenue.分析記事 • Mar 28Capital Allocation Trends At Genetec (TYO:4492) Aren't IdealIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Upcoming Dividend • Mar 23Upcoming dividend of JP¥8.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 26 June 2021. Trailing yield: 0.4%. Lower than top quartile of Japanese dividend payers (2.7%). Lower than average of industry peers (1.3%).Is New 90 Day High Low • Mar 08New 90-day low: JP¥1,846The company is down 12% from its price of JP¥2,092 on 08 December 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the IT industry, which is up 2.0% over the same period.Is New 90 Day High Low • Feb 09New 90-day low: JP¥1,926The company is down 5.0% from its price of JP¥2,030 on 11 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the IT industry, which is up 8.0% over the same period.分析記事 • Nov 23Genetec Corporation (TYO:4492) Has A ROE Of 13%Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...Is New 90 Day High Low • Oct 12New 90-day high: JP¥2,421The company is up 20% from its price of JP¥2,013 on 14 July 2020. The Japanese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the IT industry, which is up 9.0% over the same period.お知らせ • Jun 29Genetec Corporation to Report Q1, 2021 Results on Aug 05, 2020Genetec Corporation announced that they will report Q1, 2021 results on Aug 05, 2020財務状況分析短期負債: 4492の 短期資産 ( ¥4.5B ) が 短期負債 ( ¥3.0B ) を超えています。長期負債: 4492の短期資産 ( ¥4.5B ) が 長期負債 ( ¥1.2B ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: 4492の 純負債対資本比率 ( 17% ) は 満足できる 水準であると考えられます。負債の削減: 4492の負債対資本比率は、過去 5 年間で4.1%から75.6%に増加しました。債務返済能力: 4492の負債は 営業キャッシュフロー によって 十分にカバーされていません ( 5.4% )。インタレストカバレッジ: 4492の負債に対する 利息支払い は EBIT ( 29.3 x coverage) によって 十分にカバーされています。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YSoftware 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 14:04終値2026/05/29 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genetec Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Kaname FujitaIchiyoshi Research Institute Inc.Atsushi OhmachiThe Stock Research Center
分析記事 • May 16Genetec (TSE:4492) Could Easily Take On More DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Nov 11Is Genetec (TSE:4492) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Aug 02Does Genetec (TSE:4492) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • May 21With EPS Growth And More, Genetec (TSE:4492) Makes An Interesting CaseFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥44.22 (vs JP¥36.80 in FY 2025)Full year 2026 results: EPS: JP¥44.22 (up from JP¥36.80 in FY 2025). Revenue: JP¥11.0b (up 35% from FY 2025). Net income: JP¥510.0m (up 21% from FY 2025). Profit margin: 4.6% (down from 5.2% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • May 18Genetec Corporation, Annual General Meeting, Jun 26, 2026Genetec Corporation, Annual General Meeting, Jun 26, 2026.
Valuation Update With 7 Day Price Move • May 18Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥387, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 14x in the IT industry in Japan. Total returns to shareholders of 45% over the past three years.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥11.50 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 11 June 2026. Payout ratio is a comfortable 53% but the company is not cash flow positive. Trailing yield: 4.2%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.8%).
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥8.40 (vs JP¥2.18 in 3Q 2025)Third quarter 2026 results: EPS: JP¥8.40 (up from JP¥2.18 in 3Q 2025). Revenue: JP¥2.74b (up 49% from 3Q 2025). Net income: JP¥97.0m (up 288% from 3Q 2025). Profit margin: 3.5% (up from 1.4% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year whereas the company’s share price has increased by 45% per year.
お知らせ • Dec 02Genetec Corporation to Report Q3, 2026 Results on Feb 13, 2026Genetec Corporation announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Dec 02New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.5% Last year net profit margin: 6.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (3.5% net profit margin). Market cap is less than US$100m (JP¥5.11b market cap, or US$32.9m).
Upcoming Dividend • Sep 22Upcoming dividend of JP¥8.00 per shareEligible shareholders must have bought the stock before 29 September 2025. Payment date: 02 December 2025. Payout ratio is a comfortable 53% and the cash payout ratio is 96%. Trailing yield: 3.9%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.2%).
お知らせ • Sep 02Genetec Corporation to Report Q2, 2026 Results on Nov 14, 2025Genetec Corporation announced that they will report Q2, 2026 results on Nov 14, 2025
Reported Earnings • Aug 11First quarter 2026 earnings released: EPS: JP¥1.48 (vs JP¥4.56 in 1Q 2025)First quarter 2026 results: EPS: JP¥1.48 (down from JP¥4.56 in 1Q 2025). Revenue: JP¥2.49b (up 23% from 1Q 2025). Net income: JP¥17.0m (down 67% from 1Q 2025). Profit margin: 0.7% (down from 2.6% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
分析記事 • Jul 31Genetec Corporation (TSE:4492) Might Not Be As Mispriced As It LooksWith a median price-to-earnings (or "P/E") ratio of close to 14x in Japan, you could be forgiven for feeling...
お知らせ • Jun 27Genetec Corporation to Report Q1, 2026 Results on Aug 08, 2025Genetec Corporation announced that they will report Q1, 2026 results on Aug 08, 2025
Reported Earnings • May 21Full year 2025 earnings released: EPS: JP¥36.80 (vs JP¥36.38 in FY 2024)Full year 2025 results: EPS: JP¥36.80 (up from JP¥36.38 in FY 2024). Revenue: JP¥8.12b (up 14% from FY 2024). Net income: JP¥421.0m (up 1.7% from FY 2024). Profit margin: 5.2% (down from 5.8% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 20Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥432, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 18x in the IT industry in Japan. Total returns to shareholders of 79% over the past three years.
分析記事 • May 16Genetec (TSE:4492) Could Easily Take On More DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • May 16Genetec Corporation, Annual General Meeting, Jun 27, 2025Genetec Corporation, Annual General Meeting, Jun 27, 2025.
分析記事 • Apr 19Take Care Before Diving Into The Deep End On Genetec Corporation (TSE:4492)There wouldn't be many who think Genetec Corporation's ( TSE:4492 ) price-to-earnings (or "P/E") ratio of 14.3x is...
New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (JP¥4.71b market cap, or US$32.2m).
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to JP¥411, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 15x in the IT industry in Japan. Total returns to shareholders of 60% over the past three years.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 10 June 2025. Payout ratio is a comfortable 60% and this is well supported by cash flows. Trailing yield: 4.3%. Within top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.4%).
お知らせ • Mar 11Genetec Corporation to Report Fiscal Year 2025 Results on May 15, 2025Genetec Corporation announced that they will report fiscal year 2025 results on May 15, 2025
お知らせ • Feb 25Genetec Corporation (TSE:4492) agreed to acquire Morson Japan Co.,Ltd. from Yasunori Morikawa and others for ¥800 million.Genetec Corporation (TSE:4492) agreed to acquire Morson Japan Co.,Ltd. from Yasunori Morikawa and others for ¥800 million on February 25, 2025. For the period ending March 31, 2024, Morson Japan Co.,Ltd. reported total revenue of ¥2.52 billion, EBIT of ¥34 million and net income of ¥20 million. As of March 31, 2024, Morson Japan Co.,Ltd. reported total assets of ¥2.01 billion and total common equity of ¥898 million. The expected completion of the transaction is March 6, 2025.
Reported Earnings • Feb 15Third quarter 2025 earnings released: EPS: JP¥2.18 (vs JP¥6.94 in 3Q 2024)Third quarter 2025 results: EPS: JP¥2.18 (down from JP¥6.94 in 3Q 2024). Revenue: JP¥1.84b (up 3.4% from 3Q 2024). Net income: JP¥25.0m (down 68% from 3Q 2024). Profit margin: 1.4% (down from 4.5% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (JP¥5.97b market cap, or US$39.1m).
Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥520, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 18x in the IT industry in Japan. Total returns to shareholders of 93% over the past three years.
お知らせ • Jan 03Genetec Corporation to Report Q3, 2025 Results on Feb 14, 2025Genetec Corporation announced that they will report Q3, 2025 results on Feb 14, 2025
分析記事 • Nov 11Is Genetec (TSE:4492) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Buy Or Sell Opportunity • Nov 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.1% to JP¥598. The fair value is estimated to be JP¥753, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 41%.
お知らせ • Oct 01Genetec Corporation to Report Q2, 2025 Results on Nov 14, 2024Genetec Corporation announced that they will report Q2, 2025 results on Nov 14, 2024
Upcoming Dividend • Sep 20Upcoming dividend of JP¥8.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 02 December 2024. Payout ratio is a comfortable 42% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (1.4%).
Buy Or Sell Opportunity • Sep 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.2% to JP¥606. The fair value is estimated to be JP¥763, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 41%.
Reported Earnings • Aug 11First quarter 2025 earnings released: EPS: JP¥4.56 (vs JP¥1.67 loss in 1Q 2024)First quarter 2025 results: EPS: JP¥4.56 (up from JP¥1.67 loss in 1Q 2024). Revenue: JP¥2.01b (up 40% from 1Q 2024). Net income: JP¥52.0m (up JP¥71.0m from 1Q 2024). Profit margin: 2.6% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
分析記事 • Aug 05Positive Sentiment Still Eludes Genetec Corporation (TSE:4492) Following 34% Share Price SlumpUnfortunately for some shareholders, the Genetec Corporation ( TSE:4492 ) share price has dived 34% in the last thirty...
New Risk • Aug 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (JP¥5.42b market cap, or US$38.0m).
分析記事 • Aug 02Does Genetec (TSE:4492) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Valuation Update With 7 Day Price Move • Aug 02Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥574, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 18x in the IT industry in Japan. Total returns to shareholders of 115% over the past three years.
お知らせ • Jun 05Genetec Corporation to Report Q1, 2025 Results on Aug 09, 2024Genetec Corporation announced that they will report Q1, 2025 results on Aug 09, 2024
分析記事 • May 23Genetec Corporation's (TSE:4492) Popularity With Investors Under Threat As Stock Sinks 27%Genetec Corporation ( TSE:4492 ) shares have had a horrible month, losing 27% after a relatively good period...
Reported Earnings • May 21Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: JP¥36.38 (up from JP¥2.03 in FY 2023). Revenue: JP¥7.15b (up 22% from FY 2023). Net income: JP¥414.0m (up JP¥391.0m from FY 2023). Profit margin: 5.8% (up from 0.4% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 139%. Revenue is forecast to stay flat during the next 2 years compared to a 5.0% growth forecast for the IT industry in Japan. Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 36% per year.
お知らせ • May 17Genetec Corporation, Annual General Meeting, Jun 25, 2024Genetec Corporation, Annual General Meeting, Jun 25, 2024.
Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to JP¥732, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 19x in the IT industry in Japan. Total returns to shareholders of 165% over the past three years.
お知らせ • Apr 02Genetec Corporation to Report Fiscal Year 2024 Results on May 15, 2024Genetec Corporation announced that they will report fiscal year 2024 results on May 15, 2024
Upcoming Dividend • Mar 21Upcoming dividend of JP¥6.50 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 17 June 2024. Payout ratio is a comfortable 4.7% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Japanese dividend payers (3.2%). Lower than average of industry peers (1.4%).
分析記事 • Feb 26Genetec Corporation (TSE:4492) Stock Rockets 38% As Investors Are Less Pessimistic Than ExpectedGenetec Corporation ( TSE:4492 ) shares have continued their recent momentum with a 38% gain in the last month alone...
Reported Earnings • Feb 19Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: JP¥1.77b (up 30% from 3Q 2023). Net income: JP¥79.0m (up JP¥129.0m from 3Q 2023). Profit margin: 4.5% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the IT industry in Japan. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to JP¥742, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 18x in the IT industry in Japan. Total returns to shareholders of 151% over the past three years.
New Risk • Jan 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.4% average weekly change). Minor Risk Market cap is less than US$100m (JP¥7.26b market cap, or US$49.1m).
Valuation Update With 7 Day Price Move • Jan 18Investor sentiment improves as stock rises 20%After last week's 20% share price gain to JP¥637, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 19x in the IT industry in Japan. Total returns to shareholders of 92% over the past three years.
New Risk • Dec 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (JP¥5.65b market cap, or US$38.1m).
お知らせ • Nov 29Genetec Corporation to Report Q3, 2024 Results on Feb 14, 2024Genetec Corporation announced that they will report Q3, 2024 results on Feb 14, 2024
Reported Earnings • Nov 17Second quarter 2024 earnings releasedSecond quarter 2024 results: EPS: JP¥36.38. Revenue: JP¥1.72b (up 29% from 2Q 2023). Net income: JP¥138.0m (up JP¥138.0m from 2Q 2023). Profit margin: 8.0% (up from 0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the IT industry in Japan. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment improves as stock rises 25%After last week's 25% share price gain to JP¥1,320, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the IT industry in Japan. Total returns to shareholders of 42% over the past three years.
お知らせ • Sep 28Genetec Corporation to Report Q2, 2024 Results on Nov 14, 2023Genetec Corporation announced that they will report Q2, 2024 results on Nov 14, 2023
Reported Earnings • Aug 12First quarter 2024 earnings released: JP¥5.02 loss per share (vs JP¥34.94 loss in 1Q 2023)First quarter 2024 results: JP¥5.02 loss per share (improved from JP¥34.94 loss in 1Q 2023). Revenue: JP¥1.44b (up 20% from 1Q 2023). Net loss: JP¥19.0m (loss narrowed 86% from 1Q 2023). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the IT industry in Japan.
お知らせ • Jun 29Genetec Corporation to Report Q1, 2024 Results on Aug 10, 2023Genetec Corporation announced that they will report Q1, 2024 results on Aug 10, 2023
Reported Earnings • May 19Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: JP¥6.10 (down from JP¥15.02 in FY 2022). Revenue: JP¥5.86b (up 25% from FY 2022). Net income: JP¥23.0m (down 59% from FY 2022). Profit margin: 0.4% (down from 1.2% in FY 2022). Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates by 60%. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the IT industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥10.00 per share at 2.0% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 14 June 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.0%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.7%).
Reported Earnings • Feb 17Third quarter 2023 earnings released: JP¥13.22 loss per share (vs JP¥1.87 loss in 3Q 2022)Third quarter 2023 results: JP¥13.22 loss per share (further deteriorated from JP¥1.87 loss in 3Q 2022). Revenue: JP¥1.36b (up 25% from 3Q 2022). Net loss: JP¥50.0m (loss widened JP¥43.0m from 3Q 2022). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the IT industry in Japan.
お知らせ • Dec 14Genetec Corporation (TSE:4492) agreed to acquire Topwell Co., Ltd. from Yasuhide Inoue for ¥547 million.Genetec Corporation (TSE:4492) agreed to acquire Topwell Co., Ltd. from Yasuhide Inoue for ¥547 million on December 13, 2022. For the period ended March 31, 2022, Topwell reported Net assets of ¥34 million, Total assets of ¥120 million, sales of ¥186 million, Operating income of ¥9 million, and Net income of ¥3 million. Transaction is expected to close on December 14, 2022.
お知らせ • Dec 02Genetec Corporation to Report Q3, 2023 Results on Feb 14, 2023Genetec Corporation announced that they will report Q3, 2023 results on Feb 14, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: JP¥1.33b (up 25% from 2Q 2022). Net income: JP¥0 (down JP¥15.0m from profit in 2Q 2022). Profit margin: 0% (down from 1.4% in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the IT industry in Japan.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Outside Director Midori Mizutani was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 28Genetec Corporation to Report Q2, 2023 Results on Nov 14, 2022Genetec Corporation announced that they will report Q2, 2023 results on Nov 14, 2022
Reported Earnings • Aug 12First quarter 2023 earnings released: JP¥34.94 loss per share (vs JP¥19.20 profit in 1Q 2022)First quarter 2023 results: JP¥34.94 loss per share (down from JP¥19.20 profit in 1Q 2022). Revenue: JP¥1.20b (up 10.0% from 1Q 2022). Net loss: JP¥131.0m (down 285% from profit in 1Q 2022). Over the next year, revenue is forecast to grow 12%, compared to a 11% growth forecast for the industry in Japan.
お知らせ • Jul 07Genetec Corporation to Report Q1, 2023 Results on Aug 10, 2022Genetec Corporation announced that they will report Q1, 2023 results on Aug 10, 2022
Reported Earnings • May 18Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: JP¥15.02 (down from JP¥47.20 in FY 2021). Revenue: JP¥4.68b (up 15% from FY 2021). Net income: JP¥56.0m (down 68% from FY 2021). Profit margin: 1.2% (down from 4.2% in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 253%. Over the next year, revenue is forecast to grow 12%, compared to a 8.0% growth forecast for the industry in Japan.
お知らせ • May 18Genetec Corporation, Annual General Meeting, Jun 28, 2022Genetec Corporation, Annual General Meeting, Jun 28, 2022.
Board Change • Apr 27No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. GM of Management Headquarters & Director Akihiro Suzuki was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
お知らせ • Apr 08Genetec Corporation to Report Fiscal Year 2022 Results on May 16, 2022Genetec Corporation announced that they will report fiscal year 2022 results on May 16, 2022
Upcoming Dividend • Mar 23Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 08 June 2022. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (1.5%).
Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥1.87 loss per share (down from JP¥8.13 profit in 3Q 2021). Revenue: JP¥1.09b (up 13% from 3Q 2021). Net loss: JP¥7.00m (down 123% from profit in 3Q 2021). Revenue was in line with analyst estimates.
お知らせ • Jan 26Genetec Corporation (JASDAQ:4492) agreed to acquire BART Co., Ltd. from Hitoshi Fujita and others.Genetec Corporation (JASDAQ:4492) agreed to acquire BART Co., Ltd. from Hitoshi Fujita and others on January 24, 2022. The deal is subject to approval from Genetec Corporation (JASDAQ:4492) board. As of January 24, 2022 Genetec Corporation (JASDAQ:4492) board approved the deal. For the year ended September 30, 2021 BART Co., Ltd. recorded the total assets of ¥95 million, net assets of ¥42 million, sales of ¥128 million, operating profit of ¥9 million, net income ¥5 million. The deal is expected to close on January 25, 2022.
Valuation Update With 7 Day Price Move • Jan 24Investor sentiment improved over the past weekAfter last week's 19% share price gain to JP¥859, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 19x in the IT industry in Japan. Total loss to shareholders of 16% over the past year.
Reported Earnings • Nov 19Second quarter 2022 earnings released: EPS JP¥4.02 (vs JP¥8.13 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: JP¥1.07b (up 10.0% from 2Q 2021). Net income: JP¥15.0m (down 50% from 2Q 2021). Profit margin: 1.4% (down from 3.1% in 2Q 2021). The decrease in margin was driven by higher expenses.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥4.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 01 December 2021. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.0%). Lower than average of industry peers (1.2%).
Valuation Update With 7 Day Price Move • Sep 06Investor sentiment deteriorated over the past weekAfter last week's 47% share price decline to JP¥951, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 23x in the IT industry in Japan. Total loss to shareholders of 49% over the past year.
Reported Earnings • May 18Full year 2021 earnings released: EPS JP¥94.39 (vs JP¥141 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥4.08b (down 14% from FY 2020). Net income: JP¥173.0m (down 18% from FY 2020). Profit margin: 4.2% (down from 4.5% in FY 2020). The decrease in margin was driven by lower revenue.
分析記事 • Mar 28Capital Allocation Trends At Genetec (TYO:4492) Aren't IdealIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Upcoming Dividend • Mar 23Upcoming dividend of JP¥8.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 26 June 2021. Trailing yield: 0.4%. Lower than top quartile of Japanese dividend payers (2.7%). Lower than average of industry peers (1.3%).
Is New 90 Day High Low • Mar 08New 90-day low: JP¥1,846The company is down 12% from its price of JP¥2,092 on 08 December 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the IT industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Feb 09New 90-day low: JP¥1,926The company is down 5.0% from its price of JP¥2,030 on 11 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the IT industry, which is up 8.0% over the same period.
分析記事 • Nov 23Genetec Corporation (TYO:4492) Has A ROE Of 13%Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Is New 90 Day High Low • Oct 12New 90-day high: JP¥2,421The company is up 20% from its price of JP¥2,013 on 14 July 2020. The Japanese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the IT industry, which is up 9.0% over the same period.
お知らせ • Jun 29Genetec Corporation to Report Q1, 2021 Results on Aug 05, 2020Genetec Corporation announced that they will report Q1, 2021 results on Aug 05, 2020